CEO
Financial summary January –
- Net sales: KSEK 0 (0)
- Result after financial items: KSEK -9 313 (-7 173)
- Cash and cash equivalents as of
March 31 : KSEK 1 473 (26 765)
Significant events during the period January –
Lipum reports positive interim results from clinical phase 1 study showing thatSOL-116 reduces plasma BSSL levels in healthy subjects.Lipum carries out a rights issue.Lipum reports first patient included in the ongoing phase 1 clinical study.Lipum enters an agreement with NorthX Biologics for manufacturing of SOL‑116 intended for use in phase 2 clinical studies.
Significant events after the period
Lipum strengthens its protection ofSOL-116 through a patent application for inflammation-driven cancer.Lipum has been granted MSEK 2.8 funding from Swelife.Lipum announces final outcome of the rights issue thus raises proceeds of MSEK 79.7 and receives a loan commitment of MSEK 20.
CEO
The complete report (only in Swedish) is available at ww.lipum.se.
© Modular Finance, source